secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001171843-26-001098
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4
--------------------------------------------------------------------------------

- Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.
- Phase 2 prurigo nodularis and atopic dermatitis studies fully enrolled; data expected summer and late 2026.
- Phase 1 CDX-622 (bispecific SCF & TSLP) proof-of-mechanism study in mild-to-moderate asthma initiated.
- Q4 2025 net loss $81.3M ($1.22 per share) vs $47.1M ($0.71) year ago; R&D spend rose to $75.3M.
- Cash, cash equivalents and marketable securities $518.6M at Dec 31, 2025; runway through 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184326001098/0001171843-26-001098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184326001098/f8k_022526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer